Johnson & Johnson (NYSE: JNJ) announces it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (Biosense Webster) to make it a category leader in four of the largest and highest-growth medtech markets within cardiovascular intervention.
Read the full article: Johnson & Johnson Completes Acquisition of Shockwave Medical //
Source: https://www.businesswire.com/news/home/20240530938029/en/Johnson-Johnson-Completes-Acquisition-of-Shockwave-Medical